Exposure of the yeast Candida albicans to the anti-neoplastic agent adriamycin increases the tolerance to amphotericin B

The Journal of Pharmacy and Pharmacology
Joseph O'KeeffeKevin Kavanagh

Abstract

Cancer patients experience a high incidence of fungal infections due to their immuno-suppressed condition. This work has investigated the interaction of an anti-neoplastic agent, adriamycin (doxorubicin), with the yeast Candida albicans and examined whether this drug altered the susceptibility of the yeast to amphotericin B - an anti-fungal agent used for the treatment of systemic fungal infections in cancer patients. Exposure to adriamycin for 24h increased the growth of C. albicans and increased the tolerance to amphotericin B by a small, but statistically significant, extent. Growth in adriamycin-supplemented medium suppressed the respiration rate of C. albicans, which resulted in a decrease in the ergosterol content of the fungal cell membrane. The tolerance to amphotericin B was lost after exposure to adriamycin for 48 h, which coincided with a restoration in the respiration rate and the ergosterol content of the fungal cell membrane. This work demonstrated that short-term exposure (24 h) to adriamycin increased the tolerance of C. albicans for amphotericin B, which may be mediated by a decrease in the ergosterol content as a result of an adriamycin-induced disruption of oxidative phosphorylation.

References

Jan 1, 1979·Cancer Chemotherapy and Pharmacology·H S Chen, J F Gross
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J CummingsJ F Smyth
May 1, 1991·Reviews of Infectious Diseases·R Saral
Aug 3, 1993·Biochemical Pharmacology·A Skladanowski, J Konopa
Aug 1, 1996·Hematology/oncology Clinics of North America·R M Lowenthal, K Eaton
Dec 1, 1996·Trends in Pharmacological Sciences·S Hartsel, J Bolard
Jan 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·B E De Pauw
Jan 1, 1997·Mycoses·U Schuler, C Haag
Jul 14, 1999·Diagnostic Microbiology and Infectious Disease·F M Verduyn LunelA Voss
Sep 17, 1999·Journal of Clinical Microbiology·B A Arthington-SkaggsC J Morrison
Jun 10, 2000·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·A J Wardlaw
Apr 12, 2002·Lancet·Dimitrios P Kontoyiannis, Russell E Lewis
Sep 28, 2002·Biochimica Et Biophysica Acta·Eva J HelmerhorstFrank G Oppenheim

Related Concepts

Amphotericin B Colloidal Dispersion
Antibiotics, Cytotoxic
Antibiotics, Antifungal
Candida albicans
Ribodoxo
Drug Interactions
Drug Tolerance
Lumisterol

Related Feeds

Central Nervous System Fungal Infections

Central nervous system fungal infections are rare and typically occur in immunocompromised patients, such as those with HIV infection or transplant recipients. Discover the latest research on central nervous system fungal infections here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.